What is the recommended algorithm for fresh frozen plasma administration in a patient with decompensated chronic liver disease undergoing major surgery?

Algorithm for FFP Use in Coagulopathy (DCLD) Patient Posted for Major Surgery

Fresh frozen plasma should NOT be used prophylactically to correct abnormal coagulation tests in patients with decompensated chronic liver disease undergoing major surgery, as INR does not reflect true hemostatic balance and FFP transfusion is ineffective, potentially hazardous, and increases portal pressure. 1, 2

Understanding the Coagulopathy in DCLD

Patients with decompensated chronic liver disease have a "rebalanced" hemostasis, not a bleeding disorder:

• Reduced procoagulant factors (II, V, VII, X, fibrinogen) are balanced by reduced anticoagulant proteins (protein C, protein S, antithrombin)
• Elevated factor VIII and von Willebrand factor compensate for thrombocytopenia
• INR only tests a subset of procoagulant factors and is a poor predictor of bleeding risk 3, 2
• Standard coagulation tests (PT, aPTT, INR) do not reflect the true hemostatic status in advanced liver disease 1

Preoperative Assessment Algorithm

Step 1: Risk Stratification

Assess bleeding risk based on:

• Procedure type (high vs. low bleeding risk)
• Severity of cirrhosis (Child-Turcotte-Pugh score, MELD-Na)
• Platelet count (more predictive than INR)
• Presence of complications: active infection, acute kidney injury, sepsis (these may cause relative hypocoagulability) 2
• BMI (high BMI increases bleeding risk)
• Anemia (associated with increased bleeding risk) 4

Step 2: Laboratory Testing

Obtain baseline tests:

• Complete blood count with platelet count
• Fibrinogen level
• Consider viscoelastic testing (TEG/ROTEM) if available - provides global assessment of hemostasis 2, 5
• Do NOT base decisions solely on INR/PT/aPTT 1, 2

Intraoperative Management Algorithm

For Active Bleeding During Surgery:

1. Initial Response:

• Optimize surgical hemostasis first
• Maintain hemodynamic stability
• Avoid excessive volume expansion (increases portal pressure) 6, 2

2. Laboratory-Guided Transfusion:

If fibrinogen <1.0 g/L with bleeding:

• First-line: Cryoprecipitate (2 pools = 4g fibrinogen) 3
• Alternative: Fibrinogen concentrate (if available) 1
• NOT FFP - contains only ~2g fibrinogen per 4 units 3

If platelet count <50 × 10⁹/L with bleeding:

• Transfuse platelets to maintain >50 × 10⁹/L 7
• Target >100 × 10⁹/L for high-risk procedures or bleeding into confined spaces 7

If massive hemorrhage (>1 blood volume transfused):

• Use balanced transfusion ratio (RBC:FFP 1:1 to 1:1.5) 1
• This is the ONLY indication for FFP in this setting 1
• Monitor fibrinogen and maintain >1.5 g/L 3

3. Viscoelastic-Guided Approach (if available):

• Use TEG/ROTEM to guide specific factor replacement 5, 8
• Reduces FFP consumption by 40-60% 5, 8
• Targets specific defects rather than empiric transfusion

For Prophylactic Correction (Preoperatively):

DO NOT:

• Transfuse FFP to "correct" elevated INR 1, 3, 2
• Use FFP for volume replacement 7
• Routinely transfuse platelets if count >50 × 10⁹/L without bleeding 7

CONSIDER:

• Vitamin K 10mg IV/PO if prolonged antibiotic therapy, malnutrition, or malabsorption (takes >12 hours to work) 6
• Thrombopoietin receptor agonists (avatrombopag, lusutrombopag) if platelet count <50 × 10⁹/L and elective high-risk procedure 6
• Optimize hemoglobin preoperatively with iron supplementation (reduces transfusion requirements) 4
• Prothrombin complex concentrate - role uncertain, not routinely recommended 6, 4

Specific Dosing When Transfusion IS Indicated

FFP (only for massive hemorrhage):

• Dose: 10-15 mL/kg to achieve minimum 30% factor concentration 7
• Use ABO-compatible or AB FFP 3

Cryoprecipitate (for hypofibrinogenemia):

• Adult dose: 2 pools (10 units) = 4g fibrinogen 3
• Target fibrinogen >1.0 g/L (>1.5 g/L during active bleeding) 3

Platelets:

• Maintain >50 × 10⁹/L during surgery 7
• Higher threshold (>100 × 10⁹/L) for neurosurgery or ophthalmologic procedures 7

Critical Pitfalls to Avoid

1. Do not transfuse FFP based on INR alone - it worsens portal hypertension, causes volume overload, and doesn't improve hemostasis 6, 2
2. FFP transfusion increases portal pressure - can paradoxically increase bleeding risk 6, 2
3. Prophylactic platelet transfusion is ineffective in portal hypertension (poor increments, short-lived) 9
4. Avoid recombinant Factor VIIa - increases thrombotic risk without reducing bleeding 4
5. Tranexamic acid/aminocaproic acid - not recommended prophylactically; consider only as rescue therapy if bleeding occurs 6

Evidence Strength

The most recent high-quality guidelines 1, 4, 2 from 2022-2025 provide strong recommendations against prophylactic FFP based on:

• Cochrane review showing no benefit 2
• Understanding of rebalanced hemostasis in cirrhosis
• Risks of FFP (TRALI, TACO, increased portal pressure)
• Successful transfusion-free liver transplantation even with prolonged INR 4, 2

This represents a paradigm shift from older 2006 guidelines 7 which were written before the rebalanced hemostasis concept was established.